Clinical trials
Observational Oligospermia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 3 |
| Unknown status | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Clinique Ovo | 2 |
| Reproductive & Genetic Hospital of CITIC-Xiangya | 2 |
| Ankara City Hospital Bilkent | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Fecundis Lab SL | 1 |
| Hospital Italiano de Buenos Aires | 1 |
| IVI Madrid | 1 |
| Istituto Clinico Humanitas | 1 |
| National Cheng-Kung University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Oligospermia | 16 |
| Infertility, Male | 9 |
| Azoospermia | 4 |
| Asthenozoospermia | 2 |
| Infertility | 2 |
| Teratozoospermia | 2 |
| COVID-19 | 1 |
| Endocrine System Diseases | 1 |
| Primary Ovarian Insufficiency | 1 |
| Varicocele | 1 |
Trials
Showing 51 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.